Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $451,000, with full-year revenue at $2.4 million, reflecting a gross profit of $1.2 million and a gross margin of 47% for the year [20][21] - Q4 gross margin was 27%, impacted by a higher proportion of consumable revenue compared to hardware sales [20] - Total operating expenses for Q4 2025 were $21.2 million, down from $31.3 million in Q4 2024, with adjusted operating expenses at $18.3 million compared to $26.7 million in the prior year [21][22] Business Line Data and Key Metrics Changes - The company reported a focus on consumable revenue, with expectations of a more than 25% increase in the number of consumable kits run by customers in 2026 [29] - The placement program for instruments has secured 17 new customers, enhancing access to key opinion leaders in the market [6][7] Market Data and Key Metrics Changes - The company anticipates modest capital sales in 2026 due to a focus on preparing the market for the Proteus launch, which is expected at the end of 2026 [5][10] - The NIH funding environment has shown some improvement, which may positively impact customer capital expenditures [49] Company Strategy and Development Direction - The company aims to accelerate commercial adoption, deliver on its innovation roadmap, and preserve financial strength as its corporate priorities for 2025 [4][18] - The focus for 2026 is on developing the market for Proteus, with a deliberate strategy to prioritize long-term platform adoption over short-term revenue maximization [24][26] Management's Comments on Operating Environment and Future Outlook - Management views 2026 as a transition year, with expectations of limited capital sales and a focus on consumable revenue [5][24] - The company is committed to maintaining fiscal discipline while ensuring core strategic initiatives are funded appropriately [19][26] Other Important Information - The list price for Proteus has been set at $425,000, aimed at balancing premium value with accessibility for potential customers [11][78] - The company has a strong balance sheet with $215.8 million in cash and investments, allowing for strategic execution into 2028 [23][25] Q&A Session Summary Question: What are the trends in consumables within the installed base? - Management noted a consistent purchase rate from customers, with expectations of a more than 25% increase in consumable kits run by customers in 2026 [29] Question: Should we expect very few placements in 2026 with most revenue from consumables? - Management confirmed that revenue will primarily come from consumables and services, with limited capital equipment sales anticipated [31][32] Question: How should we think about the launch curve for Proteus? - Management indicated that existing Platinum users will likely transition to Proteus, while new customers may adopt at varying rates based on application availability and financial incentives [34][35] Question: Does the $98 million in guidance for operating expenses include stock compensation? - Management clarified that the adjusted operating expense number excludes stock-based compensation, focusing on cash-oriented expenses [41] Question: Is there confidence in the price point for Proteus based on customer feedback? - Management stated that the price point was released to assist customers in capital planning, with no secured orders yet but positive feedback from discussions with potential customers [45][46] Question: Will Proteus be available through leasing or rental options? - Currently, the company plans to launch Proteus with direct capital sales only, with potential for other acquisition models to be evaluated based on market feedback [81]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $451,000, with full-year revenue at $2.4 million, reflecting a gross profit of $1.2 million and a gross margin of 47% for the year [20][21] - Q4 gross margin was 27%, impacted by a higher proportion of consumable revenue compared to hardware sales [20] - Total operating expenses for Q4 2025 were $21.2 million, down from $31.3 million in Q4 2024, while full-year operating expenses were $117.3 million, compared to $110.2 million in 2024 [21][22] Business Line Data and Key Metrics Changes - The company reported a focus on consumable revenue, with expectations of a more than 25% increase in the number of consumable kits run by customers in 2026 [31] - The placement program for instruments has secured 17 new customers, enhancing access to key opinion leaders in the market [6][7] Market Data and Key Metrics Changes - The company anticipates modest capital sales in 2026 due to a focus on preparing the market for the Proteus launch, which is expected at the end of 2026 [5][12] - The NIH funding environment is showing signs of improvement, which may positively impact customer capital spending [50] Company Strategy and Development Direction - The company aims to accelerate commercial adoption, deliver on its innovation roadmap, and preserve financial strength as it prepares for the Proteus launch [4][18] - The Proteus system is expected to surpass the first-generation technology across key performance metrics, with a list price set at $425,000 to balance premium value and accessibility [12][80] Management Comments on Operating Environment and Future Outlook - Management views 2026 as a transition year, prioritizing long-term platform adoption over short-term revenue maximization [25][27] - The company is committed to maintaining fiscal discipline while ensuring core strategic initiatives are funded appropriately [19][28] Other Important Information - The company has a strong balance sheet with $215.8 million in cash and investments, allowing it to support operations into the second quarter of 2028 [24][26] - Insider ownership remains significant, with no management team members selling shares outside of plan-mandated selling for tax withholdings [28] Q&A Session Summary Question: What are the trends in consumables within the installed base? - The company is seeing consistent purchasing rates from customers, with expectations of a more than 25% increase in consumable kits run by customers in 2026 [30][31] Question: Should we expect very few placements in 2026, with most revenue from consumables? - Yes, the revenue will primarily come from consumables and services, with limited capital equipment sales anticipated [33][34] Question: Can you discuss the launch curve for Proteus? - The launch will likely follow an S-curve, with existing Platinum users transitioning to Proteus and new customers being engaged [36][39] Question: Does the $98 million in guidance for operating expenses include stock compensation? - The adjusted operating expense number excludes stock-based compensation, focusing on cash-oriented expenses [42] Question: Is the price point for Proteus based on secured pre-orders? - No secured orders are in place; the price is released to assist customers in their capital planning [46][47] Question: Will there be a rental program for Proteus? - Currently, only direct capital sales have been announced, with potential for other acquisition models to be evaluated based on market feedback [83]

Quantum-Si Investor Day Summary Company Overview - **Company**: Quantum-Si (NasdaqGM:QSI) - **Event**: 2025 Investor Day - **Date**: November 19, 2025 Industry Context - **Industry**: Proteomics - **Market Size**: Proteomics is described as a massive market with various segments including academic research, pharma, biotech, defense, and agriculture [2][3][4] - **Complexity**: The proteome consists of approximately 20,000 proteins, but the presence of post-translational modifications and isoforms leads to millions of proteoforms, making it a complex challenge [2][3] Key Points and Arguments Proteus Technology - **Proteus Program**: The majority of R&D investment is focused on the Proteus program, which aims to enhance protein sequencing capabilities [2][10] - **Architecture Change**: The Proteus architecture simplifies the imaging system, allowing for a scalable consumable with up to 80 million wells, compared to 2 million in the previous Platinum system [11][12] - **Automation and Affordability**: The new system aims to automate workflows and reduce costs, making deep protein analysis more accessible [7][12] Performance Improvements - **Sequencing Output**: Proteus is expected to produce 1.8 times more alignments per well compared to Platinum, with a significant increase in the number of wells [19][21] - **Sensitivity**: The signal-to-noise ratio (SNR) of Proteus is about twofold higher than that of Platinum, enhancing the detection of binding events [23] - **Long-Range Structural Information**: Proteus can provide deep sequencing capabilities, crucial for understanding post-translational modifications and variants [22] Future Roadmap - **Launch Timeline**: The first integrated systems are expected to be completed in Q1 2026, with a product launch planned for the end of 2026 [25][26] - **Detection of Amino Acids**: The goal is to detect all 20 amino acids by 2027, with 18 expected to be available at the launch of Proteus [48][62] - **AI and Data Utilization**: The company is leveraging AI for binder design and protein structure prediction to accelerate the development of amino acid recognizers [56][62] Additional Important Insights - **Market Challenges**: The complexity of proteomics makes traditional affinity-based approaches impractical for scaling [3][4] - **Technical Risks**: The company has focused on retiring technical risks through prototypes and has demonstrated the feasibility of the new architecture [12][13] - **Investment in R&D**: The company emphasizes that most of its investment is directed towards product development that will reach the market within the next couple of years [38][64] Conclusion Quantum-Si is positioned to make significant advancements in the proteomics field with its Proteus technology, which promises to enhance sequencing capabilities, reduce costs, and improve accessibility. The roadmap indicates a clear path towards achieving the detection of all 20 amino acids, supported by innovative technology and strategic investments in R&D.

Quantum-Si (QSI) FY Conference Summary Company Overview - **Company**: Quantum-Si (QSI) - **Industry**: Life Science Tools and Diagnostics - **Technology**: Next generation protein sequencer utilizing single molecule detection technology for amino acid detection [1][3] Core Points and Arguments Technology and Market Position - Quantum-Si is the first company to commercialize next generation protein sequencing, aiming for de novo sequencing of proteins [3][4] - The technology is currently used for targeted applications, with plans to expand sequencing output and amino acid coverage [4] Market Dynamics - **U.S. Academic Market**: Experiencing slowdowns in capital purchasing; however, consumable purchases from existing customers are ahead of expectations [5][6] - **Biopharma Market**: Positive traction with applications in protein barcoding; the company has increased opportunities from 30 to 60 in this sector [6][7] Capital Acquisition Models - New models for capital acquisition have been introduced, allowing customers to reagent rent or lease the platform, which may enhance long-term customer engagement [9][10] - A six-month evaluation period is set for customers using the device to assess usage and potential purchase [12][13] Sales Cycles - Academic sales cycles have stretched due to funding issues, while biopharma sales cycles remain longer due to the complexity of implementation [15][16] - Biopharma customers are committing significant time and resources, creating high barriers for competitors once contracts are secured [17] Utilization Patterns - Academic customers show episodic usage patterns, while biopharma customers exhibit more consistent purchasing behavior [22][23] - The platform is expected to generate consumable revenue equivalent to its list price of $125,000 annually at scale [25][26] Product Development - The launch of the Platinum Pro sequencer has been successful, offering onboard analysis capabilities and access to dyes for various applications [28][29] - Upcoming products include V3 and V4 library prep kits aimed at expanding amino acid coverage and lowering sample input requirements [31][34] PTM Detection Kits - PTM detection kits are anticipated to significantly expand the customer base and revenue potential, particularly in developed markets [36][39] - The ability to combine pre-sequencing detection with sequencing runs will enhance the depth of protein profiling [38] Future Product: Proteus - The Proteus device, set to launch in 2026, will feature a new optics-based architecture, allowing for higher density and lower production costs [41][44] - The development timeline is on track, with a prototype expected to demonstrate sequencing capabilities by the end of the year [45] AI Integration - AI is being utilized to develop amino acid recognizers and improve kinetic databases, which is expected to accelerate the path to complete proteome coverage [50][52] - The company has screened over a million binder candidates, providing a rich dataset for AI training [55][56] Additional Insights - There is a perception that the potential of Quantum-Si and its technology may be underestimated, particularly regarding the capabilities of the upcoming Proteus device [58][59] - The complexity of protein sequencing presents high barriers to entry for competitors, suggesting a strong market position for Quantum-Si [59][60]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $842,000, representing an 84% increase compared to Q1 2024, although it was slightly below expectations [7][18] - Gross profit was $486,000 with a gross margin of 58%, influenced by low or no-cost inventory utilized during the quarter [18][19] - Total operating expenses for Q1 2025 were $25.6 million, up from $23.6 million in Q1 2024, while adjusted operating expenses were $22.9 million compared to $21.9 million in the previous year [19][20] Business Line Data and Key Metrics Changes - The launch of the Platinum Pro system occurred during the first quarter, with initial customer sales reported [6][7] - Existing US academic customers continued to purchase consumables, despite a slowdown in new instrument purchases due to NIH funding uncertainties [8][19] Market Data and Key Metrics Changes - The US academic market is experiencing a slowdown in new instrument purchases, expected to persist until at least fall 2025 [7][8] - The company has 23 international distribution partners, and international business performed well during the first quarter [9][20] Company Strategy and Development Direction - The company aims to accelerate commercial adoption, deliver on its innovation roadmap, and preserve financial strength [6][10] - Emphasis is being placed on the pharma and biotech sectors in the US market due to ongoing NIH funding uncertainties [8][10] - The technology roadmap includes the launch of Version four sequencing kits in Q3 2025 and improvements in library preparation kits by the end of 2025 [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term market opportunity in proteomics despite current market uncertainties [17][23] - The company is monitoring potential impacts from evolving tariffs and has strategies in place to mitigate long-term effects [20][21] Other Important Information - The company has $232.6 million in cash and cash equivalents as of March 31, 2025, providing a runway into the second half of 2027 [20][23] - The company is focused on maintaining its technology leadership and is committed to investing wisely in R&D and commercialization efforts [45][46] Q&A Session Summary Question: Concerns about biopharma spending and tariffs - Management noted that current funding levels in biotech and pharma are stable and not significantly impacted by policy discussions [28][29] Question: Feedback on the Platinum Pro system - The system is considered locked down, with positive feedback from early adopters regarding reliability and performance [31][32] Question: Future gross margin expectations - Historical margins are expected to remain in the 40% to 50% range, with variability based on product mix and sales [37][38] Question: Cash runway and potential need for additional capital - The company has sufficient cash to sustain operations through the second half of 2027, with a focus on targeted investments [41][46] Question: International distribution partners and tariff impacts - No significant tariff impacts have been observed, and the distribution network has expanded to 23 partners covering multiple countries [49][50] Question: Sequencing kit improvements and market competition - The next version of the sequencing kit will provide meaningful performance improvements, with a focus on maintaining a competitive edge [72][76]